The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Sun Pharma announces Absorica patent litigation settlement

06-Oct-2015 | Source : Sun Pharmaceutical Industries | Visits : 7080
MUMBAI - Sun Pharmaceutical Industries Ltd. announced in a press release that Ranbaxy Pharmaceuticals Inc. (Ranbaxy), a wholly-owned subsidiary, along with its partners, Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) have entered into a Settlement Agreement with Actavis Group (Actavis) that dismisses the patent litigation suit relating to Actavis’ Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). 

As part of the Settlement Agreement, Ranbaxy, Cipher, and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica® in the US on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The other terms of the agreement are confidential. 

The Settlement Agreement is subject to review by the US Federal Trade Commission and the US Department of Justice. Absorica ® (Isotretinoin capsules) is the registered trademark of Ranbaxy Laboratories Inc. 
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. 

Related Articles